Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

Living with a chronic pain condition can make everyday tasks more challenging. For some people in Southern Utah dealing with ...

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

Research shows neuropathy can be more severe and more common in Black breast cancer patients, causing doctors to dial back ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

Out-of-pocket costs continue to increase for patients who must buy commonly prescribed drugs to treat these five neurological ...

Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic ...

When you think of the YMCA, you might think of working out. But the "Y's" Thriver's Club is about more than making your ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...

Topline results are expected in Q4 2025 and Averitas Pharma aims to submit a supplemental new drug application ... FDA approved the product for the treatment of neuropathic pain associated with ...

Aachen, Germany, & Morristown, N.J., 7 November 2024 (News Aktuell ... In 2020, the U.S. FDA approved the product for the treatment of neuropathic pain associated with diabetic peripheral neuropathy ...